Analgesics Market - Databook 2025 to 2034

The global analgesics market size surpassed USD 88.89 billion in 2024 and is predicted to reach around USD 143.42 billion by 2034, registering a CAGR of 4.9% from 2025 to 2034.

Highlights of the Analgesics Market

• North America dominated the global analgesics market in 2024.
• Asia Pacific is anticipated to grow fastest in the market during the forecast period.
• By drug class, the opioids segment held a dominant presence in the analgesics market in 2024.
• By drug class, the NSAIDs segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
• By indication, the surgical pain segment accounted for a considerable share of the analgesics market in 2024.
• By indication, the neuropathic pain segment is projected to experience the highest growth rate in the market between 2025 and 2034.
• By type, the prescription segment led the analgesics market.
• By type, the OTC segment is set to experience the fastest rate of market growth from 2025 to 2034.
• By pain type, the surgical and trauma pain segment registered its dominance over the analgesics market in 2024.
• By pain type, the musculoskeletal pain segment is anticipated to grow at the highest CAGR in the market during the studied years.
• By application, the internal analgesics segment dominated the analgesics market.
• By application, the external analgesics segment is projected to expand rapidly in the market in the coming years.
• By route of administration, the oral segment maintained a leading position in the analgesics market in 2024.
• By route of administration, the parenteral segment is predicted to witness significant growth in the market in the coming years.

Industry Valuation and Growth Rate Projection

Analgesics are medicines that are widely used to relieve pain. Unlike anesthetics administered at the time of surgery, analgesics don’t numb nerves, alter consciousness, or change the ability to sense surroundings. These medicines are widely known as pain relievers or painkillers. It helps to relieve different types of pain, from headaches to injuries to arthritis. Opioid analgesics change the way the brain perceives pain, and anti-inflammatory analgesics reduce inflammation. Pharmaceutical advancements, increased healthcare demands, and increased demand for over-the-counter (OTC) analgesics are driving the growth of the analgesics market.

• According to a report published by the Worldwide Market Reports in August 2022, the positive impact of COVID-19 on the Global Non-Narcotic Analgesics Market: Key players is expected to experience massive growth by forecast to 2028: GlaxoSmithKline PLC, Novartis AG, Sanofi S.A.

Analgesics: Stats and Figures

• In January 2025, Vertex Pharmaceutical’s drug to treat acute pain, the health regulator said, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis, was approved by the U.S. Food and Drug Administration.
• In September 2024, an entry into the topical analgesic market through its consumer business division was announced by Mankind Pharma, one of India’s leading pharmaceutical companies. With the topical analgesic market in India valued at ₹1488 crore, according to IQVIA, Mankind Pharma’s launch of Nimulid Strong arrives at a pivotal moment.

How has AI Benefited the Analgesics Market?

Artificial intelligence (AI) has many applications in pain medicines. Artificial intelligence can assist in selecting testing methods to identify causes of pain and enhance diagnostic accuracy. In clinical pain management, artificial intelligence supports the development of patient-centered treatments, like helping healthcare providers construct individualized treatment plans for musculoskeletal conditions based on symptoms, and includes commercially available AI-based mobile applications. AI is revolutionizing the process of drug development by extracting critical insights from complex multi-omics biomedical data, identifying new biomarkers, and detecting therapeutic targets and anomalies to facilitate the discovery of lead compounds and drug candidates.

Industry Leader Announcements

• Pfizer Emerging Markets President Nick Lagunowich

Pfizer Emerging Markets President Nick Lagunowich said, “We are thrilled to have reached such an incredible milestone through our continued collaboration with Gavi to ensure children around the world have the opportunity to live longer and healthier lives, but our work does not end here.”

• David A. Ricks, Lilly’s chair and CEO

David A. Ricks, Lilly’s chair and CEO, said, “Thanks to Pratik’s leadership, Lilly’s cardiometabolic health and U.S. businesses have achieved tremendous growth over the past few years.” “With these changes, we will create the additional focus we need to reach the next level. I am confident that Pratik, Ilya, and Ken will continue to advance our long-term strategy to discover, develop, and deliver medicines that can help people live longer, healthier lives.”

Geographical Insights

North America dominated the global analgesics market in 2024. Rising demand for over-the-counter (OTC) analgesics, rising public awareness about self-medication and pain management, pharmaceutical advancements, and increased healthcare awareness are driving the growth of the analgesics market.

Asia Pacific is anticipated to grow fastest in the market during the forecast period. Regulatory support, rising demand for analgesics, and technological advancements are contributing to the growth of the analgesics market in the Asia Pacific region.

Recent Developments in the Analgesics Market

• In February 2024, the launch of COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. was announced by Hikma Pharmaceuticals PLC (Hikma). COMBOGESIC IV is an intravenous, opioid free pain relief medicine that is a combination of 1000 mg of acetaminophen and 300 mg of ibuprofen, a non-steroidal anti-inflammatory drug (NSAID).
• In April 2022, the first-ever clean acetaminophen pain relief products for adults were launched, Genexa®. Genexa Acetaminophen PM caplets have the same active ingredients and dosages of current category leaders, but without artificial dyes, synthetic fillers, and other alternative preservatives.

Competitive Landscape

• Company Name: Abbott
• Year of Incorporation: 1894
• Headquarters: Chicago, Illinois, United States

More than 160 countries where it operates. It operates in the medical devices, nutritional products, diagnostics, and pharmaceuticals sector, which helps to improve aquaculture healthcare around the world.

• Company Name: Pfizer Inc.
• Year of Incorporation: 1942
• Headquarters: New York, New York, United States

More than 160 countries where it operates. It operates in the healthcare sector, including pharmaceuticals and biopharmaceutical industries, which helps to improve healthcare around the world.